Optimal medical therapy for coronary artery disease in 2011-perspectives from the STICH trial

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2011, Pages 269-276

  Whayne, Thomas F ^a   Saha, Sibu P ^b   Quevedo, Karla ^c   Mukherjee, Debabrata ^c  

^a Division of Cardiovascular Medicine   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovascular risk; Coronary artery surgery; Coronary heart disease; Lifestyle changes; Lipoproteins; Medical management; Prevention; Prognosis; Statins; Symptom relief

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; METOPROLOL; NIFEDIPINE; NITRATE; PERINDOPRIL; PRASUGREL; RANOLAZINE; TICAGRELOR; VALSARTAN; VERAPAMIL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG TOLERANCE; DRUG WITHDRAWAL; EXERCISE; GOLD STANDARD; HUMAN; ISCHEMIA; LIFESTYLE MODIFICATION; LOW DRUG DOSE; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; RISK REDUCTION; SMOKING CESSATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; HUMANS; LIFE STYLE;

EID: 82255194100     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152511798120868     Document Type: Article

References (41)

1. Mukherjee, D. Implementation of evidence-based therapies for myocardial infarction and survival. JAMA, 2011, 305(16), 1710-1711.
2. Boden, W.E.; O'Rourke, R.A.; Teo, K.K.; Hartigan, P.M.; Maron, D.J.; Kostuk, W.J.; Knudtson, M.; Dada, M.; Casperson, P.; Harris, C.L.; Chaitman, B.R.; Shaw, L.; Gosselin, G.; Nawaz, S.; Title, L.M.; Gau, G.; Blaustein, A.S.; Booth, D.C.; Bates, E.R.; Spertus, J.A.; Berman, D.S.; Mancini, G.B.; Weintraub, W.S. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med., 2007, 356(15), 1503-1516.
3. Frye, R.L.; August, P.; Brooks, M.M.; Hardison, R.M.; Kelsey, S.F.; MacGregor, J.M.; Orchard, T.J.; Chaitman, B.R.; Genuth, S.M.; Goldberg, S.H.; Hlatky, M.A.; Jones, T.L.; Molitch, M.E.; Nesto, R.W.; Sako, E.Y.; Sobel, B.E. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med., 2009, 360(24), 2503-2515.
4. Velazquez, E.J.; Lee, K.L.; Deja, M.A.; Jain, A.; Sopko, G.; Marchenko, A.; Ali, I.S.; Pohost, G.; Gradinac, S.; Abraham, W.T.; Yii, M.; Prabhakaran, D.; Szwed, H.; Ferrazzi, P.; Petrie, M.C.; O'Connor, C.M.; Panchavinnin, P.; She, L.; Bonow, R.O.; Rankin, G.R.; Jones, R.H.; Rouleau, J.L. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N. Engl. J. Med., 2011, 364(17), 1607-1616.
5. Bartecchi, C.E.; MacKenzie, T.D.; Schrier, R.W. The human costs of tobacco use (1). N. Engl. J. Med., 1994, 330(13), 907-912.
6. Benowitz, N.L.; Gourlay, S.G. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J. Am. Coll. Cardiol., 1997, 29(7), 1422-1431.
7. Counseling and interventions to prevent tobacco use and tobacco- caused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann. Intern. Med., 2009, 150(8), 551-555.
8. Haskell, W.L.; Lee, I.M.; Pate, R.R.; Powell, K.E.; Blair, S.N.; Franklin, B.A.; Macera, C.A.; Heath, G. W.; Thompson, P.D.; Bauman, A. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation, 2007, 116(9), 1081-1093.
9. Joseph, P.; Teo, K. Optimal medical therapy, lifestyle intervention, and secondary prevention strategies for cardiovascular event reduction in ischemic heart disease. Curr. Cardiol. Rep., 2011, 13(4), 287-295.
10. Patrono, C.; Coller, B.; FitzGerald, G. A.; Hirsh, J.; Roth, G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126(3 Suppl.), 234S-264S.
11. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 2002, 324(7329), 71-86.
12. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038), 1329-1339.
13. Biondi-Zoccai, G.; Lotrionte, M.; Agostoni, P.; Abbate, A.; Romagnoli, E.; Sangiorgi, G.; Angiolillo, D.J.; Valgimigle, M.; Testa, L.; Forenze, G.; Sheiban, I. Adjusted indirect comparison meta-analysis of prasugrel versul ticagrelor for patients with acute coronary syndromes. Int. J. Cardiol., 2010, 150(3), 325-331.
14. Grundy, S.M.; Cleeman, J.I.; Merz, C.N.; Brewer, H.B., Jr.; Clark, L.T.; Hunninghake, D.B.; Pasternak, R.C.; Smith, S.C., Jr.; Stone, N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 2004, 110(2), 227-239.
15. Wiviott, S.D.; Cannon, C.P.; Morrow, D.A.; Ray, K.K.; Pfeffer, M.A.; Braunwald, E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J. Am. Coll. Cardiol., 2005, 46(8), 1411-1416.
16. Hsia, J.; MacFadyen, J.G.; Monyak, J.; Ridker, P.M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J. Am. Coll. Cardiol., 2011, 57(16), 1666-1675.
17. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA, 1984, 251, 351-364.
18. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 1984, 251, 365-374.
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344(8934), 1383-1389.
20. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med., 1998, 339(19), 1349-1357.
21. Shepherd, J.; Cobbe, S.M.; Ford, I.; Isles, C.G.; Lorimer, A.R.; MacFarlane, P.W.; McKillop, J.H.; Packard, C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 1995, 333(20), 1301-1307.
22. Sacks, F.M.; Pfeffer, M.A.; Moye, L.A.; Rouleau, J.L.; Rutherford, J.D.; Cole, T.G.; Brown, L.; Warnica, J.W.; Arnold, J.M.; Wun, C.C.; Davis, B.R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med., 1996, 335(14), 1001-1009.
23. Downs, J.R.; Clearfield, M.; Weis, S.; Whitney, E.; Shapiro, D.R.; Beere, P.A.; Langendorfer, A.; Stein, E.A.; Kruyer, W.; Gotto, A.M., Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279(20), 1615-1622.
24. Sever, P.S.; Poulter, N.R.; Dahlof, B.; Wedel, H.; Beevers, G.; Caulfield, M.; Collins, R.; Kjeldsen, S. E.; Kristinsson, A.; McInnes, G.; Mehlsen, J.; Nieminen, M.S.; O'Brien, E.T.; Ostergren, J. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur. Heart J., 2008, 29(4), 499-508.
25. Byington, R.P.; Davis, B.R.; Plehn, J.F.; White, H.D.; Baker, J.; Cobbe, S.M.; Shepherd, J. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation, 2001, 103(3), 387-392.
26. Yusuf, S.; Sleight, P.; Pogue, J.; Bosch, J.; Davies, R.; Dagenais, G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med., 2000, 342(3), 145-153.
27. Fox, K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362(9386), 782-788.
28. Braunwald, E.; Domanski, M.J.; Fowler, S.E.; Geller, N.L.; Gersh, B.J.; Hsia, J.; Pfeffer, M.A.; Rice, M.M.; Rosenberg, Y.D.; Rouleau, J.L. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med., 2004, 351(20), 2058-2068.
29. Nissen, S.E.; Tuzcu, E.M.; Libby, P.; Thompson, P.D.; Ghali, M.; Garza, D.; Berman, L.; Shi, H.; Buebendorf, E.; Topol, E.J. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA, 2004, 292(18), 2217-2225.
30. Pfeffer, M.A.; McMurray, J.J.; Velazquez, E.J.; Rouleau, J.L.; Kober, L.; Maggioni, A.P.; Solomon, S. D.; Swedberg, K.; Van de Werf, F.; White, H.; Leimberger, J. D.; Henis, M.; Edwards, S.; Zelenkofske, S.; Sellers, M.A.; Califf, R.M. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med., 2003, 349(20), 1893-1906.
31. Rehnqvist, N.; Hjemdahl, P.; Billing, E.; Bjorkander, I.; Eriksson, S.V.; Forslund, L.; Held, C.; Nasman, P.; Wallen, N.H. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur. Heart J., 1996, 17(1), 76-81.
32. Dargie, H.J.; Ford, I.; Fox, K.M. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur. Heart, J., 1996, 17(1), 104-112.
33. Pepine, C.J.; Cohn, P.F.; Deedwania, P.C.; Gibson, R.S.; Handberg, E.; Hill, J.A.; Miller, E.; Marks, R.G.; Thadani, U. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation, 1994, 90(2), 762-768.
34. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-- DAVIT II). Am. J. Cardiol., 1990, 66(10), 779-785.
35. Boden, W.E.; van Gilst, W.H.; Scheldewaert, R.G.; Starkey, I.R.; Carlier, M.F.; Julian, D.G.; Whitehead, A.; Bertrand, M.E.; Col, J.J.; Pedersen, O.L.; Lie, K.I.; Santoni, J.P.; Fox, K.M. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet, 2000, 355(9217), 1751-1756.
36. Poole-Wilson, P.A.; Lubsen, J.; Kirwan, B.A.; van Dalen, F.J.; Wagener, G.; Danchin, N.; Just, H.; Fox, K.A.; Pocock, S.J.; Clayton, T.C.; Motro, M.; Parker, J.D.; Bourassa, M.G.; Dart, A.M.; Hildebrandt, P.; Hjalmarson, A.; Kragten, J.A.; Molhoek, G.P.; Otterstad, J.E.; Seabra-Gomes, R.; Soler-Soler, J.; Weber, S. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet, 2004, 364(9437), 849-857.
37. Canet, E.; Lerebours, G.; Vilaine, J.P. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine. Ann. N.Y. Acad. Sci., 2011, 1222, 90-99.
38. Ignarro, L.J. After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc Natl. Acad. Sci. USA, 2002, 99(12), 7816-7817.
39. Heidenreich, P.A.; McDonald, K.M.; Hastie, T.; Fadel, B.; Hagan, V.; Lee, B.K.; Hlatky, M.A. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA, 1999, 281(20), 1927-1936.
40. Aslam, S.; Gray, D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv. Ther., 2010, 27(4), 193-201.
41. Hsia, J.; Macfadyen, J.G.; Monyak, J.; Ridker, P.M. Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin The JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J. Am. Coll. Cardiol., 2011, 57(16), 1666-1675.